188627-80-7

188627-80-7 structure

Name: Eptifibatide acetate salt
Chemical Name: eptifibatide
CAS Number: 188627-80-7
Molecular Formula: C₃₅H₄₉N₁₁O₉S₂
Molecular Weight: 831.962
Catalog: Biochemical Peptide
Create Date: 2018-04-27 08:00:00
Modify Date: 2024-01-02 19:19:40
Eptifibatide is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.Target: OthersEptifibatide is an anti-coagulant that selectively blocks the platelet glycoprotein IIb/IIIa receptor. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarus barbouri). It belongs to the class of the so called arginin-glycin-aspartat-mimetics and reversibly binds to platelets [1, 2].

Name	eptifibatide
Synonyms	[(3R,11S,17S,20S,25aS)-11-(4-Carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid Integrilin 7H-Pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosine-17-acetic acid, 3-(aminocarbonyl)-11-[4-[(aminoiminomethyl)amino]butyl]docosahydro-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-, (3R,11S,17S,20S,25aS)- Eptifibatide

Description	Eptifibatide is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.Target: OthersEptifibatide is an anti-coagulant that selectively blocks the platelet glycoprotein IIb/IIIa receptor. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarus barbouri). It belongs to the class of the so called arginin-glycin-aspartat-mimetics and reversibly binds to platelets [1, 2].
Related Catalog	Signaling Pathways >> Cytoskeleton >> Integrin Research Areas >> Cardiovascular Disease Peptides
References	[1]. Amoroso, G., et al., Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease. J Cardiovasc Pharmacol, 2001. 38(4): p. 633-41. [2]. Schwarz, M., et al., Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther, 2004. 308(3): p. 1002-11.